Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of SLV320 Added to Chronic Furosemide on Renal Function in Congestive Heart Failure
2007-000490-40Phase 2Completed
- Sponsor
- Solvay Pharmaceuticals
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of derenofylline in heart failure (HF) and chronic kidney disease (CKD) (6 arms), sponsored by Solvay Pharmaceuticals. Primary endpoint: Change in cystatin C from baseline to Day 85. Started May 2007; status: completed.
02
Drugs
derenofylline
03
Conditions
heart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2007-000490-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000490-40.